cystatin 13 Activators
Cst13, identified as cystatin 13, emerges as a crucial player in cellular processes, leveraging its predicted function as an inhibitor of cysteine-type endopeptidases. Positioned upstream of negative regulation of peptidase activity, this gene exhibits a versatile functional role predicted to extend into both the cytoplasm and the extracellular region. The selective expression of Cst13 in the testis further emphasizes its specialization within reproductive tissues. Its orthologous relationship with human CST13P, a pseudogene, adds an intriguing layer to its evolutionary conservation, suggesting potential functional significance in maintaining cellular homeostasis and responding to environmental cues.
The activation of Cst13 involves intricate molecular mechanisms orchestrated by a diverse array of chemical activators. Direct activation pathways include histone deacetylase inhibition and DNA demethylation, fostering an open chromatin structure and demethylated gene promoter, respectively. These processes enhance Cst13 expression by creating a conducive environment for transcription. Additionally, indirect activation is achieved through inhibitors targeting critical signaling pathways such as TGF-β, MAPK/ERK, PI3K/AKT, NF-κB, STAT3, JAK/STAT, and Wnt. By blocking these pathways, negative regulation on Cst13 is alleviated, leading to increased gene expression and subsequent upregulation. This complex regulatory network underscores the adaptability of Cst13 in responding to a myriad of cellular signals, highlighting its pivotal role in maintaining cellular integrity and modulating essential cellular processes. Exploring the comprehensive landscape of Cst13 and its activation mechanisms not only advances our understanding of its function but also lays the groundwork for potential implications in broader biological contexts.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A, an HDAC Inhibitor, directly activates Cst13 by inhibiting histone deacetylation, promoting an open chromatin structure that enhances Cst13 expression and facilitates its upregulation. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
5-Azacytidine, a DNA methyltransferase inhibitor, directly activates Cst13 by influencing DNA demethylation, leading to a demethylated state in the gene promoter and enhanced Cst13 transcription. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
SB431542, a TGF-β Receptor Inhibitor, indirectly stimulates Cst13 by blocking the TGF-β signaling pathway, relieving negative regulation and promoting increased Cst13 expression and subsequent upregulation. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126, a MAPK/ERK Inhibitor, indirectly activates Cst13 by blocking the MAPK/ERK pathway, relieving negative regulation and leading to increased Cst13 expression and subsequent upregulation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002, a PI3K Inhibitor, indirectly stimulates Cst13 by blocking the PI3K/AKT pathway, alleviating negative regulation and promoting enhanced Cst13 expression and subsequent upregulation. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $62.00 $85.00 $356.00 | 155 | |
Bay 11-7082, an NF-κB Inhibitor, indirectly activates Cst13 by inhibiting the NF-κB pathway, relieving negative regulation and enhancing Cst13 expression, contributing to its upregulation. | ||||||
Stat3 inhibitor V, stattic | 19983-44-9 | sc-202818 sc-202818A sc-202818B sc-202818C sc-202818D sc-202818E sc-202818F | 25 mg 100 mg 250 mg 500 mg 1 g 2.5 g 5 g | $130.00 $196.00 $274.00 $512.00 $731.00 $1408.00 $2091.00 | 114 | |
Stattic, a STAT3 Inhibitor, indirectly stimulates Cst13 by blocking the STAT3 pathway, relieving negative regulation and promoting increased Cst13 expression and subsequent upregulation. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
Ruxolitinib, a JAK Inhibitor, indirectly activates Cst13 by blocking the JAK/STAT pathway, relieving negative regulation and facilitating enhanced Cst13 expression and subsequent upregulation. | ||||||
XAV939 | 284028-89-3 | sc-296704 sc-296704A sc-296704B | 1 mg 5 mg 50 mg | $36.00 $117.00 $525.00 | 26 | |
XAV-939, a Wnt Pathway Inhibitor, indirectly stimulates Cst13 by blocking the Wnt signaling pathway, relieving negative regulation and promoting increased Cst13 expression and upregulation. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $133.00 $275.00 | 37 | |
Suberoylanilide Hydroxamic Acid, an HDAC Inhibitor, directly activates Cst13 by inhibiting histone deacetylation, fostering an open chromatin structure that enhances Cst13 expression and facilitates its upregulation. | ||||||